ReviewJournal of oncology2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in
Abstract readReview
In one paragraph
Review in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Liquid biopsy: a new window on the BRCA genes.ESMO open · 2026Review
- Towards sustainable hereditary breast and ovarian cancer surveillance: insights from a single-center survey.Journal of human genetics · 2026Article
- Temporal changes in breast cancer lifetime risk and implications for personalised surveillance in high-risk women.Insights into imaging · 2026Article
- Global, Regional, and National Burden of Breast Cancer Attributable to Low Physical Activity in Women of Reproductive Age: Historical Trends from 1990 to 2021 and Projections to 2035.Archives of Iranian medicine · 2025Article
- Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?JCO precision oncology · 2025Observational
- Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome.Communications medicine · 2025Article
- Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.Breast cancer research and treatment · 2024Article
- Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimates.NPJ genomic medicine · 2024Article
- Information needs of Lynch syndrome and BRCA 1/2 mutation carriers considering risk-reducing gynecological surgery: a qualitative study of the decision-making process.Hereditary cancer in clinical practice · 2024Article
- Article
- Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles.Nature communications · 2023Article
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Gastric Cancer Risk and Pathogenesis inCancers · 2022Review
- Actionable secondary findings following exome sequencing of 836 non-obstructive azoospermia cases and their value in patient management.Human reproduction (Oxford, England) · 2022Article
- Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.JCO precision oncology · 2022Article
- Article
- Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.JCO precision oncology · 2021Article
- Review
- Malignant salivary gland tumours in families with breast cancer susceptibility.Virchows Archiv : an international journal of pathology · 2021Article
- Fluorescence Sheds Light on DNA Damage, DNA Repair, and Mutations.Trends in cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Boudewijn DullensDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-9391-1684
Robin de PutterDepartment of Medical Genetics, Ghent University Hospital, Ghent, Belgium.ORCID https://orcid.org/0000-0001-9410-8941
Matteo LambertiniDepartment of Medical Oncology, U.O.C Clinica di Oncologia Médica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.ORCID https://orcid.org/0000-0003-1797-5296
Angela TossDepartment of Oncology and Hematology, University Hospital of Modena, Modena, Italy.ORCID https://orcid.org/0000-0002-1854-6701
Sileny HanMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Els Van NieuwenhuysenMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Toon Van GorpMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Adriaan VandersticheleMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Chantal Van OngevalMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Machteld KeupersMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0001-6872-5751
Renate PrevosMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Valerie CelisMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Jeroen DekervelDigestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Wouter EveraertsDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-3157-7115
Hans WildiersDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
Ines NevelsteenMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0003-4380-7413
Patrick NevenMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Dirk TimmermanDepartment of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-3707-6645
Ann SmeetsMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-5091-6602
Ellen DenayerMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0001-6478-181X
Griet Van BuggenhoutMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.
Eric LegiusMultidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0003-2410-6996
Kevin PunieDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-1162-7963
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germline pathogenic alterations in the breast cancer susceptibility genes 1 (
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.